Role of chemotherapy in relapsed ovarian cancer

被引：16

作者：

Colombo, N ^{[1
]}

Parma, G ^{[1
]}

Bocciolone, L ^{[1
]}

Sideri, M ^{[1
]}

Franchi, D ^{[1
]}

Maggioni, A ^{[1
]}

机构：

[1] European Inst Oncol, Div Gynecol, Milan, Italy

来源：

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY | 1999年 / 32卷 / 03期

关键词：

D O I：

10.1016/S1040-8428(99)00049-9

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

[No abstract available]

引用

页码：221 / 228

页数：8

共 54 条

[21] ORAL ETOPOSIDE IS ACTIVE AGAINST PLATINUM-RESISTANT EPITHELIAL OVARIAN-CANCER [J].

HOSKINS, PJ ;

SWENERTON, KD .

JOURNAL OF CLINICAL ONCOLOGY, 1994, 12 (01) :60-63

[22]

HUININK WT, 1996, P AN M AM SOC CLIN, V15, P284

[23] Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer [J].

Huinink, WTB ;

Gore, M ;

Carmichael, J ;

Gordon, A ;

Malfetano, J ;

Hudson, I ;

Broom, C ;

Scarabelli, C ;

Davidson, N ;

Spanczynski, M ;

Bolis, G ;

Malmstrom, H ;

Coleman, R ;

Fields, SC ;

Heron, JF .

JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (06) :2183-2193

[24] RELATIONSHIPS BETWEEN CARBOPLATIN EXPOSURE AND TUMOR RESPONSE AND TOXICITY IN PATIENTS WITH OVARIAN-CANCER [J].

JODRELL, DI ;

EGORIN, MJ ;

CANETTA, RM ;

LANGENBERG, P ;

GOLDBLOOM, EP ;

BURROUGHS, JN ;

GOODLOW, JL ;

TAN, S ;

WILTSHAW, E .

JOURNAL OF CLINICAL ONCOLOGY, 1992, 10 (04) :520-528

[25]

KAVANAGH J, 1994, P AN M AM SOC CLIN, V13, P237

[26] PHASE-II STUDY OF PROLONGED ORAL ETOPOSIDE IN REFRACTORY OVARIAN-CANCER [J].

KAVANAGH, JJ ;

TRESUKOSOL, D ;

DELEON, CG ;

EDWARDS, CL ;

FREEDMAN, RS ;

HORD, M ;

HOWELL, E ;

LENZI, R ;

KRAKOFF, IH ;

KUDELKA, AP .

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 1995, 5 (05) :351-354

[27] Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma [J].

Kudelka, AP ;

Tresukosol, D ;

Edwards, CL ;

Freedman, RS ;

Levenback, C ;

Chantarawiroj, P ;

deLeon, CG ;

Kim, EE ;

Madden, T ;

Wallin, B ;

Hord, M ;

Verschraegen, C ;

Raber, M ;

Kavanagh, JJ .

JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (05) :1552-1557

[28] HIGH-DOSE IFOSFAMIDE - CIRCUMVENTION OF RESISTANCE TO STANDARD-DOSE IFOSFAMIDE IN ADVANCED SOFT-TISSUE SARCOMAS [J].

LECESNE, A ;

ANTOINE, E ;

SPIELMANN, M ;

LECHEVALIER, T ;

BRAIN, E ;

TOUSSAINT, C ;

JANIN, N ;

KAYITALIRE, L ;

FONTAINE, F ;

GENIN, J ;

VANEL, D ;

CONTESSO, G ;

TURSZ, T .

JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (07) :1600-1608

[29] HEXAMETHYLMELAMINE AS A SINGLE 2ND-LINE AGENT IN OVARIAN-CANCER [J].

MANETTA, A ;

MACNEILL, C ;

LYTER, JA ;

SCHEFFLER, B ;

PODCZASKI, ES ;

LARSON, JE ;

SCHEIN, P .

GYNECOLOGIC ONCOLOGY, 1990, 36 (01) :93-96

[30] IFOSFAMIDE AND MESNA IN PREVIOUSLY TREATED ADVANCED EPITHELIAL OVARIAN-CANCER - ACTIVITY IN PLATINUM-RESISTANT DISEASE [J].

MARKMAN, M ;

HAKES, T ;

REICHMAN, B ;

LEWIS, JL ;

RUBIN, S ;

JONES, W ;

ALMADRONES, L ;

PIZZUTO, F ;

HOSKINS, W .

JOURNAL OF CLINICAL ONCOLOGY, 1992, 10 (02) :243-248

← 1 2 3 4 5 6 →